CanSino Biologics Inc. (HKG:6185)
Hong Kong · Delayed Price · Currency is HKD 22.44
+0.08 (0.36%)
Jun 18, 2026, 4:08 PM HKT
CanSino Biologics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, CanSino Biologics stock has a consensus rating of "Strong Buy" and an average price target of $48.98. The average 1-year stock price forecast is 118.27% higher than the current stock price, while the lowest is $43.00 (+91.62%) and the highest is $53.69 (+139.26%).
Price Target: $48.98 (+118.27%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CanSino Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Oct '25 | Dec '25 | Jan '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 4 | 5 |
Financial Forecast
Revenue This Year
1.43B
from 1.07B
Increased by 33.69%
Revenue Next Year
1.79B
from 1.43B
Increased by 25.65%
EPS This Year
0.50
from 0.16
Increased by 205.81%
EPS Next Year
1.30
from 0.50
Increased by 160.00%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.5B | ||
| Avg | 1.4B | ||
| Low | 1.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 37.5% | ||
| Avg | 33.7% | ||
| Low | 30.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.50 | ||
| Avg | 0.50 | ||
| Low | 0.50 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 205.8% | ||
| Avg | 205.8% | ||
| Low | 205.8% |